Skye Bioscience, Inc. Common Stock - Asset Resilience Ratio
Skye Bioscience, Inc. Common Stock (SKYE) has an Asset Resilience Ratio of 46.14% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Skye Bioscience, Inc. Common Stock's Asset Resilience Ratio has changed over time. Check Skye Bioscience, Inc. Common Stock strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Skye Bioscience, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SKYE market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $8.96 Million | 46.14% |
| Total Liquid Assets | $8.96 Million | 46.14% |
Asset Resilience Insights
- Very High Liquidity: Skye Bioscience, Inc. Common Stock maintains exceptional liquid asset reserves at 46.14% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Skye Bioscience, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Skye Bioscience, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Skye Bioscience, Inc. Common Stock (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Skye Bioscience, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 70.12% | $19.85 Million | $28.31 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $72.76 Million | -- |
| 2023-12-31 | -76.05% | $-9.08 Million | $11.94 Million | -77.11pp |
| 2015-12-31 | 1.07% | $37.50K | $3.51 Million | -- |
About Skye Bioscience, Inc. Common Stock
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company wa… Read more